PARP enzyme inhibition is a rational, specific approach in the ever-growing field of oncology. There are ongoing studies with drug combinations as well as investigations of potential utility in other malignancies. Current data support the use of PARP inhibitors to prolong PFS, but the drug class has yet to demonstrate statistically significant improvements in OS. Pharmacists should remain involved with other members of the healthcare team, in order to educate patients regarding PARP inhibitors' adverse effects and their management.
The authors wish to acknowledge Hearn Jay Cho, MD, PhD, for his professional guidance and support.
US Pharmacist. 2018;43(9):HS10-HS17. © 2018 Jobson Publishing